We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




"Ultra-Rapid" Testing in the OR Could Enable Accurate Removal of Brain Tumors

By LabMedica International staff writers
Posted on 26 Feb 2025

For many cancers, including brain tumors, the success of surgery and the prevention of cancer recurrence depend on removing as much of the tumor and surrounding cancerous cells as safely as possible. More...

Surgeons, however, often lack information about the genetic mutations present in the tumors they are removing. Certain cancer types can be identified through specific mutations, which are changes in the DNA instructions of the abnormal cells. A technology that allows for the rapid and accurate quantification of mutations in the operating room could enable surgeons to tailor their approach based on the cancer's genetic profile, thereby improving the ability to remove tumor tissue more reliably. Researchers have now developed a groundbreaking technology capable of measuring mutation levels in tissues in just 15 minutes, paving the way for surgeries guided by genetic data and offering the potential for better patient outcomes. This tool for quickly identifying the genetic "fingerprints" of cancer cells could allow future surgeons to more precisely remove brain tumors while the patient is still in the operating room.

The study, led by researchers from NYU Langone Health (New York, NY, USA), presents the development of Ultra-Rapid droplet digital PCR (UR-ddPCR), which was found to measure the concentration of tumor cells in a tissue sample in only 15 minutes. The technology is capable of detecting as few as five cancer cells per square millimeter. According to the researchers, UR-ddPCR, at least in initial tests on brain tissue samples, is fast and accurate enough to be the first practical tool for detecting cancer cells in real-time during brain surgeries, directly using genetic mutations. To develop UR-ddPCR, the research team sought efficiencies in the steps of the standard droplet digital PCR (ddPCR) method. By reducing the DNA extraction time from 30 minutes to under five minutes, the team maintained compatibility with ddPCR. Further time savings were achieved by increasing the concentrations of chemicals used during testing, which shortened the time for some steps from two hours to under three minutes.

Additional efficiencies were realized by using pre-warmed reaction vessels for the two temperatures required by PCR, rather than repeatedly cycling the temperature of a single vessel. In the study, the researchers employed UR-ddPCR to measure the levels of two genetic mutations, IDH1 R132H and BRAF V600E, both commonly found in brain cancers. By combining UR-ddPCR with stimulated Raman histology—another technique the team developed earlier—the researchers could assess both the fraction and density of tumor cells within each tissue sample. The study, published in Cell Press Journal Med online, demonstrated that UR-ddPCR outperformed standard ddPCR in terms of processing speed. While standard ddPCR can accurately quantify tumor cells, it takes several hours to yield results, making it impractical for use during surgery.

With UR-ddPCR, surgeons could potentially determine the cancerous nature of cells and precisely quantify the number of cancer cells present in specific tissue areas, a level of accuracy previously unattainable. The study revealed that UR-ddPCR produced results consistent with both standard ddPCR and genetic sequencing across 75 tissue samples from 22 patients undergoing glioma tumor surgery at NYU Langone, a type of brain cancer. Results from UR-ddPCR were also verified against known cancer cell samples as well as non-cancerous samples. Although the tool has shown promising results, the researchers caution that broader use will require further refinement and clinical trials. The next step is to automate the UR-ddPCR process to simplify and speed up its application in the operating room. Clinical trials will also be necessary to evaluate patient outcomes when using this tool as compared to existing diagnostic methods. Additionally, the team plans to develop the technology to detect other genetic mutations commonly associated with various cancer types.

"Our study shows that Ultra-Rapid droplet digital PCR could be a fast and efficient tool for making a molecular diagnosis during surgery for brain cancer, and it has potential to also be used for cancers outside the brain," said study co-senior investigator Gilad Evrony, MD, PhD.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.